WO2003090693A3 - Pharmaceutical composition containing lamotrigine particles of defined morphology - Google Patents

Pharmaceutical composition containing lamotrigine particles of defined morphology Download PDF

Info

Publication number
WO2003090693A3
WO2003090693A3 PCT/US2003/013002 US0313002W WO03090693A3 WO 2003090693 A3 WO2003090693 A3 WO 2003090693A3 US 0313002 W US0313002 W US 0313002W WO 03090693 A3 WO03090693 A3 WO 03090693A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition containing
lamotrigine particles
defined morphology
containing lamotrigine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/013002
Other languages
French (fr)
Other versions
WO2003090693A2 (en
Inventor
Judith Aronhime
Guy Samburski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Priority to US10/511,987 priority Critical patent/US20050238724A1/en
Priority to AU2003234240A priority patent/AU2003234240A1/en
Priority to DE60312670T priority patent/DE60312670T2/en
Priority to CA002483103A priority patent/CA2483103A1/en
Priority to EP03728552A priority patent/EP1496864B1/en
Publication of WO2003090693A2 publication Critical patent/WO2003090693A2/en
Publication of WO2003090693A3 publication Critical patent/WO2003090693A3/en
Priority to IL16474304A priority patent/IL164743A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a pharmaceutical composition comprising a plurality of lamotrigine particles having a specific surface area of from about two to about three and a half meters per gram. Pharmaceutical compositions falling within the surface area criteria for the lamotrigine particles include those having a particle diameter equal to or less than about 100 µm, preferably about 50 µm, and most preferably 10 µm. The pharmaceutical composition can be formulated into a wide variety of dosage forms.
PCT/US2003/013002 2002-04-23 2003-04-23 Pharmaceutical composition containing lamotrigine particles of defined morphology Ceased WO2003090693A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/511,987 US20050238724A1 (en) 2002-04-23 2003-04-23 Pharmaceutical composition containing lamotrigine particles of defined morphology
AU2003234240A AU2003234240A1 (en) 2002-04-23 2003-04-23 Pharmaceutical composition containing lamotrigine particles of defined morphology
DE60312670T DE60312670T2 (en) 2002-04-23 2003-04-23 PHARMACEUTICAL COMPOSITION CONTAINING LAMOTRIGINE PARTICLES WITH DEFINED MORPHOLOGY
CA002483103A CA2483103A1 (en) 2002-04-23 2003-04-23 Pharmaceutical composition containing lamotrigine particles of defined morphology
EP03728552A EP1496864B1 (en) 2002-04-23 2003-04-23 Pharmaceutical composition containing lamotrigine particles of defined morphology
IL16474304A IL164743A0 (en) 2002-04-23 2004-10-20 Pharmaceutical composition containing lamotrigine particles of defined morphology

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37492302P 2002-04-23 2002-04-23
US60/374,923 2002-04-23

Publications (2)

Publication Number Publication Date
WO2003090693A2 WO2003090693A2 (en) 2003-11-06
WO2003090693A3 true WO2003090693A3 (en) 2004-01-08

Family

ID=29270569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/013002 Ceased WO2003090693A2 (en) 2002-04-23 2003-04-23 Pharmaceutical composition containing lamotrigine particles of defined morphology

Country Status (9)

Country Link
US (1) US20050238724A1 (en)
EP (1) EP1496864B1 (en)
AT (1) ATE357217T1 (en)
AU (1) AU2003234240A1 (en)
CA (1) CA2483103A1 (en)
DE (1) DE60312670T2 (en)
ES (1) ES2282628T3 (en)
IL (1) IL164743A0 (en)
WO (1) WO2003090693A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
WO2004064808A1 (en) * 2003-01-15 2004-08-05 Dow Global Technologies Inc. Drug particles obtained by freezing onto a cold surface
US20080269223A1 (en) * 2004-04-06 2008-10-30 Saibal Chakravorty Mouth Dissolvable and Meltable, and Water Dispersable Delivery Formulation
US20100016322A1 (en) * 2007-02-28 2010-01-21 Nagesh Nagaraju Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
US20090196924A1 (en) * 2008-02-04 2009-08-06 Pramod Kharwade Controlled-release lamotrigine formulations
RU2476206C1 (en) 2011-11-22 2013-02-27 Виктор Львович Лимонов Pharmaceutical composition for preparing infusion solutions of antimicrobial preparations, method for preparing it (versions)
CN105982879B (en) * 2015-02-03 2019-01-29 复旦大学附属华山医院 A lamotrigine polymer micelle drug delivery system targeting epilepsy foci
EP3525792A4 (en) * 2016-10-11 2020-04-22 Aucta Pharmaceuticals Powder for oral suspension containing lamotrigine
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
US12514860B2 (en) * 2021-04-16 2026-01-06 Shanghai Aucta Pharmaceuticals Co., Ltd. Composition containing lamotrigine, and preparation method and use thereof
CN114948868B (en) 2021-04-16 2023-04-14 上海奥科达医药科技股份有限公司 A crystal form of lamotrigine hydrate, its preparation method and composition comprising it
CN122497490A (en) 2023-11-03 2026-07-31 杜理斯制药公司 Instant non-aqueous solutions of lamotrigine
US12605388B2 (en) 2024-09-25 2026-04-21 Azurity Pharmaceuticals Ireland Limited Lamotrigine salts, co-crystals, and compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8604019A1 (en) * 1985-04-15 1986-01-16 Nippon Shinyaku Co Ltd Di:chloro-benzoguanamine powder prepn.
WO1996017611A1 (en) * 1994-12-07 1996-06-13 The Wellcome Foundation Limited Pharmaceutical composition comprising lamotrigine
WO1997000681A1 (en) * 1995-06-23 1997-01-09 The Wellcome Foundation Limited Pharmaceutical composition containing lamotrigine
WO2001022938A1 (en) * 1999-09-24 2001-04-05 Janssen Pharmaceutica N.V. Antiviral compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL124029B1 (en) * 1979-06-01 1982-12-31 Wellcome Found Process for preparing novel derivatives of 1,2,4-triazine
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US5643591A (en) * 1991-01-16 1997-07-01 Fmc Corporation Solid dosage forms
US5531925A (en) * 1991-10-04 1996-07-02 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
US6525185B1 (en) * 1998-05-07 2003-02-25 Affymetrix, Inc. Polymorphisms associated with hypertension
US6639072B1 (en) * 2000-01-03 2003-10-28 Rpg Life Sciences Limited Process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
EP1292582A1 (en) * 2000-06-08 2003-03-19 Merck & Co., Inc. 4-benzyl-2-hydroxy-1,4-oxazin-3-one and polymorphic forms thereof
WO2002045691A2 (en) * 2000-12-06 2002-06-13 Pharmacia Corporation Laboratory scale milling process
CA2439468A1 (en) * 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. New crystal forms of lamotrigine and processes for their preparations
US7049322B2 (en) * 2002-02-21 2006-05-23 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
US20040247689A1 (en) * 2003-03-26 2004-12-09 Guy Samburski Process for preparing a pharmaceutical active ingredient with high specific surface area

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8604019A1 (en) * 1985-04-15 1986-01-16 Nippon Shinyaku Co Ltd Di:chloro-benzoguanamine powder prepn.
WO1996017611A1 (en) * 1994-12-07 1996-06-13 The Wellcome Foundation Limited Pharmaceutical composition comprising lamotrigine
WO1997000681A1 (en) * 1995-06-23 1997-01-09 The Wellcome Foundation Limited Pharmaceutical composition containing lamotrigine
WO2001022938A1 (en) * 1999-09-24 2001-04-05 Janssen Pharmaceutica N.V. Antiviral compositions

Also Published As

Publication number Publication date
CA2483103A1 (en) 2003-11-06
EP1496864B1 (en) 2007-03-21
IL164743A0 (en) 2005-12-18
AU2003234240A1 (en) 2003-11-10
US20050238724A1 (en) 2005-10-27
ATE357217T1 (en) 2007-04-15
EP1496864A2 (en) 2005-01-19
ES2282628T3 (en) 2007-10-16
DE60312670T2 (en) 2007-12-06
WO2003090693A2 (en) 2003-11-06
AU2003234240A8 (en) 2003-11-10
DE60312670D1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
HUP0401567A3 (en) Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
AU2003234240A1 (en) Pharmaceutical composition containing lamotrigine particles of defined morphology
WO2003032953A1 (en) Granules containing acid-unstable chemical in large amount
MEP2108A (en) Crystalline composition containing escitalopram
MXPA05007635A (en) Personal cleansing composition containing irregularly shaped particles and spherical particles.
EP0965343A3 (en) Ziprasidone formulations
HUP0400246A3 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
IL159086A0 (en) 3-aryl-5-aryl- [1, 2, 4] -oxadiazole derivatives and pharmaceutical compositions containing the same
PT1418890E (en) Propellant-based microparticle formulations
IL160108A0 (en) Pharmaceutical compositions containing beta-lapachone or derivatives or analogs thereof, and methods of using same
CA2348451A1 (en) Dosage forms containing taste masked active agents
HUP0303825A3 (en) 1h-benzimidazole and 3h-imidazo-[4,5b]pyridine-derivatives, their use and pharmaceutical compositions containing them
IL163366A (en) Glucocorticoid mimetics, pharmaceutical compositions thereof and uses thereof for the preparation of pharmaceutical compositions
WO2006002140A3 (en) Compositions comprising amphotericin b
HUP0303724A3 (en) Chemokine receptors inhibitor bipiperidinyl-derivatives and pharmaceutical compositions containing them and process for preparation of the compounds
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
AU2002221702A1 (en) Pharmaceutical compositions
AU2003277839A1 (en) Physical methods of dispersing characteristics use particles and compositions thereof
IL162185A0 (en) Phenylpropionate derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
HUP0002037A3 (en) Hydroximic acid derivatives, use of them for producing pharmaceutical compositions suitable for inhibiting matrix metalloproteinas and pharmaceutical compositions containing the compounds
HUP0000678A3 (en) Aminobenzophenones as inhibitors of interleukin and tnf, process for their preparation and pharmaceutical compositions containing the same
HUP0400179A3 (en) 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them
CA2384188A1 (en) Antiviral compositions
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003728552

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2483103

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10511987

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003728552

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWG Wipo information: grant in national office

Ref document number: 2003728552

Country of ref document: EP